vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $151.7M, roughly 1.3× Nutex Health, Inc.). Nutex Health, Inc. runs the higher net margin — 7.8% vs -14.6%, a 22.4% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 50.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
AXSM vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $151.7M |
| Net Profit | $-28.6M | $11.8M |
| Gross Margin | — | 30.4% |
| Operating Margin | -13.8% | 20.4% |
| Net Margin | -14.6% | 7.8% |
| Revenue YoY | 65.0% | -41.1% |
| Net Profit YoY | 61.9% | -80.8% |
| EPS (diluted) | $-0.55 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $151.7M | ||
| Q3 25 | $171.0M | $267.8M | ||
| Q2 25 | $150.0M | $244.0M | ||
| Q1 25 | $121.5M | $211.8M | ||
| Q4 24 | $118.8M | $257.6M | ||
| Q3 24 | $104.8M | $78.8M | ||
| Q2 24 | $87.2M | $76.1M | ||
| Q1 24 | $75.0M | $67.5M |
| Q4 25 | $-28.6M | $11.8M | ||
| Q3 25 | $-47.2M | $55.4M | ||
| Q2 25 | $-48.0M | $-17.7M | ||
| Q1 25 | $-59.4M | $21.2M | ||
| Q4 24 | $-74.9M | $61.6M | ||
| Q3 24 | $-64.6M | $-8.8M | ||
| Q2 24 | $-79.3M | $-364.0K | ||
| Q1 24 | $-68.4M | $-364.0K |
| Q4 25 | — | 30.4% | ||
| Q3 25 | — | 57.8% | ||
| Q2 25 | — | 51.2% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | — | 55.0% | ||
| Q3 24 | — | 27.8% | ||
| Q2 24 | — | 29.7% | ||
| Q1 24 | — | 15.1% |
| Q4 25 | -13.8% | 20.4% | ||
| Q3 25 | -27.0% | 48.7% | ||
| Q2 25 | -24.5% | 13.8% | ||
| Q1 25 | -46.9% | 38.1% | ||
| Q4 24 | -61.1% | 44.4% | ||
| Q3 24 | -59.8% | 12.3% | ||
| Q2 24 | -89.5% | 7.0% | ||
| Q1 24 | -89.7% | 2.1% |
| Q4 25 | -14.6% | 7.8% | ||
| Q3 25 | -27.6% | 20.7% | ||
| Q2 25 | -32.0% | -7.3% | ||
| Q1 25 | -48.9% | 10.0% | ||
| Q4 24 | -63.1% | 23.9% | ||
| Q3 24 | -61.7% | -11.2% | ||
| Q2 24 | -91.0% | -0.5% | ||
| Q1 24 | -91.1% | -0.5% |
| Q4 25 | $-0.55 | $2.34 | ||
| Q3 25 | $-0.94 | $7.76 | ||
| Q2 25 | $-0.97 | $-2.95 | ||
| Q1 25 | $-1.22 | $3.33 | ||
| Q4 24 | $-1.54 | $11.56 | ||
| Q3 24 | $-1.34 | $-1.72 | ||
| Q2 24 | $-1.67 | $-0.07 | ||
| Q1 24 | $-1.44 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $329.4M |
| Total Assets | $689.8M | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $185.6M | ||
| Q3 25 | $325.3M | $166.0M | ||
| Q2 25 | $303.0M | $96.7M | ||
| Q1 25 | $300.9M | $84.7M | ||
| Q4 24 | $315.4M | $40.6M | ||
| Q3 24 | $327.3M | $46.9M | ||
| Q2 24 | $315.7M | $40.8M | ||
| Q1 24 | $331.4M | $30.0M |
| Q4 25 | $88.3M | $329.4M | ||
| Q3 25 | $73.7M | $317.2M | ||
| Q2 25 | $73.1M | $235.3M | ||
| Q1 25 | $53.2M | $176.9M | ||
| Q4 24 | $57.0M | $132.4M | ||
| Q3 24 | $92.9M | $60.4M | ||
| Q2 24 | $102.9M | $62.7M | ||
| Q1 24 | $144.0M | $63.0M |
| Q4 25 | $689.8M | $918.5M | ||
| Q3 25 | $669.3M | $964.5M | ||
| Q2 25 | $639.8M | $841.0M | ||
| Q1 25 | $596.7M | $761.9M | ||
| Q4 24 | $568.5M | $655.3M | ||
| Q3 24 | $561.5M | $438.5M | ||
| Q2 24 | $548.2M | $422.4M | ||
| Q1 24 | $545.7M | $404.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $70.4M |
| Free Cash FlowOCF − Capex | $-18.7M | $69.0M |
| FCF MarginFCF / Revenue | -9.6% | 45.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $70.4M | ||
| Q3 25 | $1.0M | $99.5M | ||
| Q2 25 | $-32.4M | $27.3M | ||
| Q1 25 | $-43.4M | $51.0M | ||
| Q4 24 | $-26.2M | $54.0K | ||
| Q3 24 | $-18.6M | $6.8M | ||
| Q2 24 | $-30.1M | $13.3M | ||
| Q1 24 | $-53.5M | $3.1M |
| Q4 25 | $-18.7M | $69.0M | ||
| Q3 25 | $988.0K | $99.2M | ||
| Q2 25 | $-32.4M | $26.5M | ||
| Q1 25 | $-43.7M | $50.9M | ||
| Q4 24 | $-26.2M | $-341.0K | ||
| Q3 24 | $-18.7M | $6.2M | ||
| Q2 24 | $-30.2M | $12.7M | ||
| Q1 24 | $-53.6M | $2.3M |
| Q4 25 | -9.6% | 45.5% | ||
| Q3 25 | 0.6% | 37.0% | ||
| Q2 25 | -21.6% | 10.9% | ||
| Q1 25 | -36.0% | 24.0% | ||
| Q4 24 | -22.1% | -0.1% | ||
| Q3 24 | -17.9% | 7.8% | ||
| Q2 24 | -34.6% | 16.7% | ||
| Q1 24 | -71.4% | 3.4% |
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.3% | 0.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.1% | 0.8% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
| Q4 25 | — | 5.95× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
